Many competitors achieve monodispersity by first using cytotoxic CTAB templates, then swapping ligands for citrate. This approach introduces:

• Higher costs from multi-step processing
• Incomplete ligand exchange risks (leaving toxic CTAB residues)
• Batch variability from uneven surface replacement

Our rigorous quality controls ensure identical performance across batches, saving you months of troubleshooting inconsistent materials.

Applications Ready for Reliable Results

• Biomedical platforms: CTAB-free surfaces accelerate FDA-compliant studies
• Sensing & diagnostics: Precise plasmonic responses for reproducible assays
• Catalysis R&D: Uniform surface areas for accurate activity comparisons
• Nano-bio interfaces: Stable citrate layers simplify ligand conjugation

Ready to elevate your research with truly reproducible nanomaterials?

Contact us for technical specifications and pricing! We're happy to provide high-resolution TEM images demonstrating our particles' exceptional monodispersity and detailed characterization data to help you make an informed decision.